RHX 552
Alternative Names: RHX-552Latest Information Update: 28 Jan 2024
At a glance
- Originator Rheos Medicines
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA
- 28 Jan 2024 No recent reports of development identified for research development in Rheumatoid-arthritis in USA
- 10 Mar 2021 RHX 552 is available for licensing as of 10 Mar 2021. https://rheosrx.com/